Evidence map›Paper›PMID 40103991›Full record

ReviewRSC advances2025

Advances in isoxazole chemistry and their role in drug discovery.

Glanish Jude Martis, Santosh L Gaonkar

Abstract readReview
In one paragraph

Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Study of Cytotoxicity of Pyrrolo[3,4-International journal of molecular sciences · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Synthetic Strategies to Access Fluorinated Azoles.European journal of organic chemistry · 2025
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Glanish Jude MartisDepartment of Chemistry, Manipal Institute of Technology, Manipal Academy of Higher Education Manipal 576104 Karnataka India sl.gaonkar@manipal.edu.
Santosh L GaonkarDepartment of Chemistry, Manipal Institute of Technology, Manipal Academy of Higher Education Manipal 576104 Karnataka India sl.gaonkar@manipal.edu.ORCID https://orcid.org/0000-0003-2687-6927

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Isoxazoles are a class of five-membered heterocyclic compounds that have gained significant attention in medicinal chemistry due to their diverse biological activities and therapeutic potential. Recent advances in isoxazole chemistry have led to the development of novel synthetic strategies, enabling the creation of a wide array of isoxazole derivatives with enhanced bioactivity and selectivity. This review explores the latest progress in isoxazole synthesis, highlighting key methodologies such as transition metal-catalyzed cycloadditions, green chemistry approaches, and regioselective functionalization techniques. These advances have not only improved the efficiency of isoxazole synthesis but have also facilitated the design of more complex and bioactive derivatives. In addition to their synthetic advances, isoxazoles have demonstrated a broad spectrum of biological activities, including antimicrobial, anticancer, anti-inflammatory, and neuroprotective effects, making them attractive candidates in drug discovery. This review discusses the structural modifications that enhance their pharmacological properties and their potential for developing therapies for diseases such as cancer, neurodegenerative disorders, and infections. Moreover, we examine the emerging trends in isoxazole-based drug discovery, such as the development of multi-targeted therapies and personalized medicine approaches. The evolving role of isoxazoles in drug discovery underscores their continued importance in modern pharmaceutical research and their potential to address unmet medical needs.

Identifiers

PMID40103991
PMCPMC11912359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.